Adoptive Immunotherapy With Engineered T Cells Expressing and HLA-A2 Restricted Affinity-Enhanced TCR for LAGE-1 and NY-ESO-1 in Patients With Multiple Myeloma Following Auto-SCT

Journal for ImmunoTherapy of Cancer - United Kingdom
doi 10.1186/2051-1426-1-s1-p30
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy